UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 145

Sortiert nach

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

Oncogene, 2007-10, Vol.26 (45), p.6469-6487

MOASSER, M. M

2007

Link zum Volltext

Verfügbarkeit prüfen

Targeting the function of the HER2 oncogene in human cancer therapeutics

Oncogene, 2007-10, Vol.26 (46), p.6577-6592

MOASSER, M. M

2007

Link zum Volltext

Verfügbarkeit prüfen

epidermal growth factor receptor family: Biology driving targeted therapeutics

Cellular and molecular life sciences : CMLS, 2008-05, Vol.65 (10), p.1566-1584

2008

Link zum Volltext

Verfügbarkeit prüfen

Targeting HER proteins in cancer therapy and the role of the non-target HER3

British journal of cancer, 2007-08, Vol.97 (4), p.453-457

2007

Link zum Volltext

Verfügbarkeit prüfen

HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13), p.3645-3658

2018

Link zum Volltext

Verfügbarkeit prüfen

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers

Scientific reports, 2021-04, Vol.11 (1), p.9091-11, Article 9091

2021

Link zum Volltext

Verfügbarkeit prüfen

The Evolving Landscape of HER2 Targeting in Breast Cancer

JAMA oncology, 2015-11, Vol.1 (8), p.1154

2015

Link zum Volltext

Verfügbarkeit prüfen

A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src

Cell reports (Cambridge), 2018-10, Vol.25 (2), p.449-463.e4

2018

Link zum Volltext

Verfügbarkeit prüfen

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Nature, 2007-01, Vol.445 (7126), p.437-441

2007

Link zum Volltext

Verfügbarkeit prüfen

The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics

Seminars in cell & developmental biology, 2010-12, Vol.21 (9), p.944-950

2010

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

British journal of cancer, 2011-06, Vol.104 (12), p.1828-1835

2011

Link zum Volltext

Verfügbarkeit prüfen

Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions

Cancer research (Chicago, Ill.), 2022-08, Vol.82 (16), p.2811-2820

Moasser, Mark M.

2022

Link zum Volltext

Verfügbarkeit prüfen

The tyrosine kinase inhibitor ZD1839 (iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells

Cancer research (Chicago, Ill.), 2001-10, Vol.61 (19), p.7184-7188

2001

Link zum Volltext

Verfügbarkeit prüfen

Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3′-Kinase/Akt Pathway Signaling

Clinical cancer research, 2003-10, Vol.9 (12), p.4340-4346

2003

Link zum Volltext

Verfügbarkeit prüfen

The HER family and cancer: emerging molecular mechanisms and therapeutic targets

Trends in molecular medicine, 2007-12, Vol.13 (12), p.527-534

2007

Link zum Volltext

Verfügbarkeit prüfen

Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum

Oncogene, 2015-10, Vol.34 (41), p.5288-5294

2015

Link zum Volltext

Verfügbarkeit prüfen

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling

Cell reports (Cambridge), 2022-02, Vol.38 (5), p.110285-110285, Article 110285

2022

Link zum Volltext

Verfügbarkeit prüfen

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver

Science translational medicine, 2010-01, Vol.2 (16), p.16ra7

2010

Link zum Volltext

Verfügbarkeit prüfen

Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A

Biochemical pharmacology, 2021-01, Vol.183, p.114317-114317, Article 114317

2021

Link zum Volltext

Verfügbarkeit prüfen

HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells

Biochemical journal, 2012-11, Vol.447 (3), p.417-425

2012

Link zum Volltext

Verfügbarkeit prüfen

Cellular Mechanisms of Resistance to Anthracyclines and Taxanes in Cancer: Intrinsic and Acquired

Seminars in oncology, 2008-04, Vol.35 (2 Suppl 2), p.S1-S14

2008

Link zum Volltext

Verfügbarkeit prüfen

Two Dimensions in Targeting HER2

Journal of clinical oncology, 2014-07, Vol.32 (19), p.2074-2077

MOASSER, Mark M

2014

Link zum Volltext

Verfügbarkeit prüfen

Targeting HER2 by Combination Therapies

Journal of clinical oncology, 2018-03, Vol.36 (8), p.808-811

2018

Link zum Volltext

Verfügbarkeit prüfen

A tumor-suppressing function in the epithelial adhesion protein Trask

Oncogene, 2012-01, Vol.31 (4), p.419-431

2012

Link zum Volltext

Verfügbarkeit prüfen

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy

Clinical cancer research, 2010-03, Vol.16 (5), p.1373-1383

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 145

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(138)
Mit Volltextzugriff
(133)

Publikationsform

Sprache

Englisch
(145)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(30)
Cancer Research
(15)
Clinical Cancer Research
(11)
Oncogene
(11)
Breast Cancer Research And Treatment
(9)
Cell Cycle
(5)
Cell Reports
(4)
Biochemical Journal
(3)
European Journal Of Cancer
(3)
Molecular Cancer Therapeutics
(3)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

Targeting the function of the HER2 oncogene in human cancer therapeutics

epidermal growth factor receptor family: Biology driving targeted therapeutics

Targeting HER proteins in cancer therapy and the role of the non-target HER3

HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers

The Evolving Landscape of HER2 Targeting in Breast Cancer

A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions

The tyrosine kinase inhibitor ZD1839 (iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells

Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3′-Kinase/Akt Pathway Signaling

The HER family and cancer: emerging molecular mechanisms and therapeutic targets

Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver

Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A

HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells

Cellular Mechanisms of Resistance to Anthracyclines and Taxanes in Cancer: Intrinsic and Acquired

Two Dimensions in Targeting HER2

Targeting HER2 by Combination Therapies

A tumor-suppressing function in the epithelial adhesion protein Trask

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy

Suchergebnisse filtern